FDA Proposes Permanent End to Bulk GLP-1 Compounding — Comment by June 29

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the regulatory mechanism that governs which drug ingredients large-scale compounding facilities can use. If finalized, this would permanently remove the pathway for outsourcing facilities to compound these GLP-1 medications at scale.

This is different from the enforcement actions you may have read about earlier this year. Those targeted specific companies breaking existing rules. This proposal would change the rules themselves.

What's the 503B Bulks List?

Two types of pharmacies compound medications in the United States:

• 503A pharmacies — Traditional compounding pharmacies that fill individual patient prescriptions, one at a time, based on a specific doctor's order. These operate under state pharmacy boards.
• 503B outsourcing facilities — Larger-scale operations that can compound without individual prescriptions and distribute to healthcare facilities. They're FDA-registered and inspected, and they can only compound using ingredients on the "503B Bulks List."

During the GLP-1 shortages (2022–2025), both types of pharmacies were legally compounding semaglutide and tirzepatide. Now that the shortages are resolved, the FDA is proposing to formally exclude these drugs from the 503B list — meaning outsourcing facilities can no longer compound them at scale, even if a future shortage occurs.

Why the FDA Is Doing This

The FDA's rationale, as stated in the May 1, 2026 Federal Register notice:

• FDA-approved versions of all three drugs are now available without shortage
• The agency found "no clinical need" for compounded versions when FDA-approved alternatives exist
• Over 455 adverse event reports were linked to compounded semaglutide, and over 320 to compounded tirzepatide — many involving dosing errors from multi-dose vials
• Concerns about counterfeit products entering the market through online channels

The Public Comment Period

The FDA has opened the proposal for public comment. If you have opinions about this decision — whether as a patient, provider, or pharmacy professional — you can submit them through the Federal Register.

What This Means If You're on Compounded GLP-1

If you're currently taking compounded semaglutide or tirzepatide from a telehealth provider, here's the practical impact:

If your provider uses a 503A pharmacy: Your supply chain is not directly affected by this proposal. 503A patient-specific compounding operates under a different legal framework.

If your provider uses a 503B outsourcing facility: Your supply could be affected if/when the proposal is finalized. The timeline isn't immediate — the comment period runs through June 29, and the FDA will review comments before making a final determination.

Regardless of your current source: It's worth having a conversation with your provider about their supply chain and contingency plans. Ask whether they source from 503A or 503B facilities.

The Bigger Picture

This proposal is part of a broader shift. Brand-name manufacturers have aggressively reduced prices — Novo Nordisk's self-pay Wegovy is now approximately $349/month, down from over $1,300. Oral pills are launching. Medicare coverage is arriving in July. The market dynamics that made compounding necessary are changing.

But price parity isn't here yet. Compounded GLP-1s still run $99–$299/month versus $349+ for brand-name. For patients paying out of pocket, the cost difference remains meaningful. The FDA's position is that safety, not cost, should determine the compounding landscape.